| Filing Date |
Form |
Description |
|
| June 24, 2025 |
6-K |
On June 19, 2025, Biophytis S.A. issued a press release announcing the temporary suspension of the trading of its shares. |
 |
| June 4, 2025 |
6-K |
On June 4, 2025, Biophytis S.A. issued a press release announcing its participation in the BIO International Convention from June 16 to 19. |
|
| June 2, 2025 |
6-K |
On June 2, 2025, Biophytis S.A. issued a press release announcing that, due to exceptional circumstances related to technical complications in the audit process, the publication of its 2024 annual financial statements has been postponed. |
|
| May 15, 2025 |
6-K |
On May 15, 2025, Biophytis S.A. issued a press release announcing its active participation at the 32nd European Congress on Obesity (ECO 2025). |
|
| April 29, 2025 |
20-F |
Notification of Late Filing (Form NT 20-F) for Biophytis SA due to management resources focused on refinancing (€2.5M gross, €2.2M net), delaying the annual report (Form 20-F) filing for fiscal year ended December 31, 2024, expected within the allowed 15-day extension. |
|
| April 25, 2025 |
6-K |
On April 25, 2025, Biophytis S.A. issued a press release announcing the postponement of the publication of the annual financial statements. |
|
| April 22, 2025 |
6-K |
On April 22, 2025, Biophytis S.A. issued a press release announcing that the company targets mobility restoration in patients with obesity. |
|
| April 8, 2025 |
6-K |
On April 8, 2025, Biophytis S.A. issued a press release confirming the Launch of the phase 2 OBA Clinical Trial in Obesity. |
|
| March 28, 2025 |
6-K |
On March 28, 2025, Biophytis S.A. issued a press release announcing the settlement and delivery of its €2.6 million private placement. |
|
| March 26, 2025 |
6-K |
On March 26, 2025, Biophytis S.A. issued a press release announcing the successful completion of a €2.6 million private placement. |
|
| January 21, 2025 |
6-K |
On January 21, 2025, Biophytis S.A. issued a press release announcing the signing of a co-development agreement with AskHelpU, the largest association in China for those affected by amyotrophic lateral sclerosis (ALS). |
|
| January 14, 2025 |
6-K |
On January 14, 2025, Biophytis S.A. issued a press release announcing that the company enters exclusive negotiations with a Chinese pharmaceutical company to license BIO101. |
|
| January 6, 2025 |
6-K |
On January 6, 2025, Biophytis S.A. (the “Company”) issued a press release announcing the temporary suspension of the listing of its ordinary shares and share warrants on the Euronext Growth market. |
|
| September 30, 2024 |
6-K |
On September 30, 2024, Biophytis S.A. (the “Company”) issued its Interim Financial Report for the first half of fiscal year 2024. |
|
| July 22, 2024 |
6-K |
On July 22, 2024, Biophytis S.A. issued a press release announcing the deployment of its partnership strategy in Asia. |
|
| July 11, 2024 |
6-K |
On July 11, 2024, Biophytis S.A. issued a press release announcing that Biophytis obtains IND approval from the FDA to start its phase 2 OBA study in obesity. |
|
| July 1, 2024 |
6-K |
On July 1, 2024, Biophytis S.A. issued a press release announcing the presentation of its Phase 2-3 COVA study results in severe forms of COVID-19 at the WCID in Paris. |
|
| June 20, 2024 |
6-K |
On June 20, 2024, Biophytis S.A. issued a press release announcing that Biophytis grants Blanver exclusive rights to BIO101 in Latin America in deal valued at up €108 Million. |
|
| June 20, 2024 |
6-K |
On June 19, 2024, Biophytis S.A. issued a press release announcing that Biophytis extends its contract with Atlas to secure financing for its business activities. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K. |
|
| June 14, 2024 |
6-K |
On June 12, 2024, Biophytis S.A. issued a press release announcing the successful industrial transfer of BIO101 (20-hydroxyecdysone) production by its service provider Seqens. |
|
| June 11, 2024 |
6-K |
On June 10, 2024, Biophytis S.A. issued a press release announcing filing of IND application with the US FDA for its phase 2 study in obesity. |
|
| June 7, 2024 |
6-K |
On June 7, 2024, Biophytis S.A. issued a press release announcing that it will hold a Combined General Meeting (CGM) on June 24, 2024. |
|
| May 14, 2024 |
6-K |
On May 14, 2024, Biophytis S.A. issued a press release announcing the design of its phase 2 OBA clinical study in obesity. |
|
| April 29, 2024 |
6-K |
On April 29, 2024, Biophytis S.A. issued a press release announcing the implementation of a dedicated strategy for partner search in obesity. |
|
| April 25, 2024 |
6-K |
On April 24, 2024, Biophytis S.A. issued a press release announcing the transfer of ADSs to OTC market. |
|
| April 18, 2024 |
6-K |
On April 18, 2024, Biophytis S.A. issued a press release announcing the formation of a new Scientific Advisory Board for its phase 2 OBA clinical study in obesity. |
|
| April 15, 2024 |
6-K |
On April 15, 2024, Biophytis S.A. issued a press release announcing the filing of a patent application and that the company strengthens its intellectual property
in obesity. |
|
| April 9, 2024 |
6-K |
On April 8, 2024, Biophytis S.A. issued a press release announcing its 2023 financial results and provides an update on its business activities. |
|
| April 9, 2024 |
6-K |
On April 8, 2024, Biophytis S.A. issued a press release announcing that it launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone). |
|
| April 8, 2024 |
20-F |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the fiscal year ended December 31, 2023. |
|
| April 5, 2024 |
6-K |
On April 4, Biophytis S.A. issued a press release announcing the results of the Combined General Meeting on April 2, 2024. |
|
| March 22, 2024 |
6-K |
On March 22, 2024, Biophytis S.A. issued a press release announcing that the company presented its phase 3 protocol in the treatment of sarcopenia at the International Conference on Frailty and Sarcopenia Research (ICFSR) held from March 20 to 22, 2024 in Albuquerque, NM, USA. |
|
| March 18, 2024 |
6-K |
On March 18, 2024, Biophytis S.A. issued a press release announcing that a Combined General Meeting will be held on April 2, 2024. |
|
| March 15, 2024 |
6-K |
On March 15, 2024, Biophytis S.A. issued a press release announcing the implementation of a reserve stock split of its ordinary shares. |
|
| March 12, 2024 |
6-K |
On March 12, 2024, Biophytis S.A. issued a press release announcing its participation in several events in Europe and the United States over the coming months. |
|
| March 8, 2024 |
6-K |
On March 8, 2024, Biophytis S.A. issued a press release announcing that the company presented the results of its recent clinical trials with Ruvembri™ at the
Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, held from 3 to 6 March 2024 in Orlando, USA. |
|
| January 5, 2024 |
6-K |
On January 4, 2024, Biophytis S.A. issued a press release announcing the publication of the results of its COV A phase 2-3 study in, eClinicalMedicine, part of The Lancet. |
|
| January 5, 2024 |
6-K |
On December 29, 2023, Biophytis S.A. issued a press release announcing the drawing of the fourth tranche of ORNANE under the 2021 Atlas Contract. |
|
| December 11, 2023 |
6-K |
On December 11, 2023, Biophytis S.A. issued a press release announcing its participation in several conferences in Europe and the US during the first quarter of 2024. |
|
| December 05, 2023 |
6-K |
On December 4, 2023, Biophytis S.A. issued a press release announcing that Biophytis and the University of Liège explore the potential of Sarconeos (Ruvembri) in the treatment of viral respiratory failure. |
|
| November 21, 2023 |
6-K |
On November 17, 2023, Biophytis S.A. issued a press release announcing receipt of Nasdaq Notice. |
|
| November 20, 2023 |
6-K |
On November 20, 2023, Biophytis S.A. issued a press release announcing the success of its capital increase with preferential subscription rights for approximately € 1.96 million. |
|
| November 7, 2023 |
6-K |
On November 6, 2023, Biophytis S.A. issued a press release announcing that the company is attending the BIO-Europe conference held in Munich, Germany, November 6th to 8th 2023. |
|
| October 30, 2023 |
6-K |
On October 30, 2023, Biophytis S.A. issued a press release announcing that Biophytis and Innovation Solutions Pharma sign a partnership agreement to accelerate market access for Sarconeos (Ruvembri) in Brazil. |
|
| October 26, 2023 |
6-K |
On October 27, 2023, Biophytis S.A. issued a press release, a copy of which is attached as Exhibit 99.1 to this Form 6-K. |
|
| October 23, 2023 |
6-K |
On October 23, 2023, Biophytis S.A. issued a press release announcing the launch of a rights issue with maintenance of shareholders’ preferential subscription rights to continue the execution of its strategic roadmap. |
|
| September 27, 2023 |
6-K |
On September 27, 2023, Biophytis S.A. (the “Company”) issued its Interim Financial Report for the first half of fiscal year 2023. |
|
| September 25, 2023 |
6-K |
On September 25, 2023, Biophytis S.A. issued a press release announcing that Biophytis and Skyepharma have signed a Partnership Agreement for the Production of Sarconeos (Ruvembri). |
|
| September 19, 2023 |
6-K |
On September 19, 2023, Biophytis S.A. issued a press release providing an update on its early access programs for Sarconeos (Ruvembri) in the treatment of severe forms of COVID-19. |
|
| September 14, 2023 |
6-K |
On September 14, 2023, Biophytis S.A. issued a press release announcing that Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer. |
|
| September 11, 2023 |
6-K |
On September 11, 2023, Biophytis S.A. issued a press release announcing that it has obtained FDA Authorization to initiate the SARA-31 phase 3 study in sarcopenia. |
|
| September 4, 2023 |
6-K |
On September 4, 2023, Biophytis S.A. issued a press release announcing its participation at the H. C. Wainwright 25th Global Investment Conference in New York. |
|
| August 16, 2023 |
6-K |
On August 16, 2023, Biophytis S.A. issued a press release announcing next regulatory steps in Europe and the United States for its COVA project. |
|
| August 8, 2023 |
6-K |
On August 8, 2023, Biophytis S.A. issued a press release announcing that it received a positive opinion for its SARA-31 phase 3 study in sarcopenia in Europe. |
|
| July 21, 2023 |
6-K |
On July 18, 2023, Biophytis S.A. entered into an investor subscription agreement with an institutional investor, pursuant to which the Company agreed to sell and issue to the investor 505,000 units of ordinary shares with ordinary warrants attached. |
|
| July 20, 2023 |
6-K |
On July 20, 2023, Biophytis S.A. issued a press release announcing it has requested a pre-submission meeting with the FDA for an Emergency Use Authorization of Sarconeos (Ruvembri) for the treatment for COVID 19. |
|
| July 19, 2023 |
6-K |
On July 19, 2023, Biophytis S.A. issued a press release announcing $3.8 Million Registered Direct Offering |
|
| July 18, 2023 |
6-K |
On July 18, 2023, Biophytis S.A. issued a press release announcing that Biophytis and Seqens have signed a partnership to produce Sarconeos (Ruvembri) active compound. |
|
| July 10, 2023 |
6-K |
On July 10, 2023, Biophytis S.A. issued a press release announcing it has filed with the FDA for authorization to initiate SARA-31 phase 3 study in sarcopenia. |
|
| July 3, 2023 |
F-3 |
F-3
Registration Statement |
|
| July 3, 2023 |
20-F/A |
Amendment No.1 to Form 20-F/A filed on April 19, 2023. |
|
| June 19, 2023 |
6-K |
On June 19, 2023, Biophytis S.A. issued a press release announcing that it reports clinical results for Sarconeos (Ruvembri) in sarcopenia treatment at the 16th SCWD International Congress. |
|
| June 16, 2023 |
6-K |
On June 16, 2023, Biophytis S.A. issued a press release announcing the approval by a large majority of all resolutions presented by the company and falling within the remit of the Annual General Meeting. |
|
| June 5, 2023 |
6-K |
On June 5, 2023, Biophytis S.A. issued a press release announcing its participation at the BIO International Convention in Boston from the 5th to the 8th of June. |
|
| May 26, 2023 |
6-K |
On May 26, 2023, Biophytis S.A. issued a press release announcing that the company has filed with the French National Authority for Health (HAS) an application for Early Access Authorisation (EAA) for Sarconeos (Ruvembri). |
|
| May 25, 2023 |
6-K |
On May 25, 2023, Biophytis S.A. issued a press release announcing its presentation of positive results of Phase 2-3 COVA study at the American Thoracic Society International Conference. |
|
| May 15, 2023 |
6-K |
On May 15, 2023, Biophytis S.A. issued a press release announcing that the company has filed with the EMA for authorization to initiate SARA-31 phase 3 study in sarcopenia. |
|
| May 11, 2023 |
6-K |
On May 11, 2023 Biophytis S.A. issued a press release announcing a successful capital increase with €2.3 million raised. |
|
| May 9, 2023 |
6-K |
On May 9, 2023, Biophytis S.A. issued a press release announcing it has requested a pre-submission meeting with the EMA for the Marketing Authorisation of Sarconeos (Ruvembri) for the treatment of COVID-19 |
|
| May 2, 2023 |
6-K |
On May 2, 2023, On May 2, 2023, Biophytis S.A. issued a press release announcing the strengthening of its management team. |
|
| April 28, 2023 |
6-K |
On April 28, 2023, Biophytis S.A. issued a press release announcing receipt of Nasdaq Notice. |
|
| April 19, 2023 |
6-K |
On April 19, 2023, Biophytis S.A. issued a press release announcing that Biophytis regains compliance with NASDAQ minimum bid price requirement. |
|
| April 19, 2023 |
20-F/A |
Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended December 31, 2022 |
|
| April 18, 2023 |
6-K |
On April 18, 2023, Biophytis S.A. issued a press release announcing 2022 Financial Results and 2023 Perspectives. A copy of the press release is attached as Exhibit 99.1 to this Form 6-K. |
|
| March 31, 2023 |
6-K |
On March 31, 2023, Biophytis S.A. issued a press release informing that the Extraordinary General Meeting of the company held on March 30, 2023 could not be held on first notice, as the required quorum was not reached. The quorum necessary for holding an extraordinary General Meeting on first call IS 25%. |
|
| March 27, 2023 |
6-K |
On March 27, 2023, Biophytis S.A. issued a press release announcing the presentation of Sarconeos (Ruvembri) as a possible treatment candidate for long COVID after hospitalization during the 13th annual International Conference on Frailty and Sarcopenia Research (ICFSR). |
|
| March 20, 2023 |
6-K |
On March 20, 2023, Biophytis S.A. issued a press release announcing the presentation of Sarconeos’ (Ruvembri) Development as a Drug Candidate in Rare Neuromuscular Diseases at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. |
|
| March 17, 2023 |
6-K |
On March 17, 2023, Biophytis S.A. issued a press release announcing ratio change under its American Depository Receipt (“ADR”) program. |
|
| March 09, 2023 |
6-K |
On March 9, 2023, Biophytis S.A. issued a press release presenting positive results of Phase 2-3 COVA Study at ERS 2023 21st Lung Science Conference. |
|
| March 02, 2023 |
6-K |
On March 2nd, 2023, Biophytis S.A. issued a press release announcing the signature of a master service agreement with Intsel Chimos, a pharmaceutical company that will operate Sarconeos (Ruvembri) in France for the treatment of severe forms of COVID-19. |
|
| February 23, 2023 |
6-K |
On February 23, 2023, Biophytis S.A. issued a press release announcing it is convening an Extraordinary and Ordinary Shareholder’s Meeting for March 30, 2023. |
|
| February 02, 2023 |
6-K |
On February 2, 2023, Biophytis S.A. issued a press release announcing positive final results of the phase 2-3 COVA study with Sarconeos (B10101) in severe COVID-19. |
|
| January 31, 2023 |
6-K |
On January 31, 2023, Biophytis S.A. issued a press release announcing the publication of its interim financial report for the first half of 2022 and its adjusted financial results as of 31 December 2021. |
|
| January 31, 2023 |
20-F/A |
Annual report pursuant to section 13 or 15(d) of the securities exchange act of 1934 |
|
| January 30, 2023 |
6-K |
On January 30, 2023, Biophytis S.A. (the “Company” issued its Interim Financial Report for the first half of fiscal year 2022. |
|
| January 19, 2023 |
6-K |
On January 19, 2023, Biophytis S.A. issued a press release announcing that the Paris Court of appeal confirms the judgement of the Paris Commercial Court of 16th March 2021. |
|
| January 06, 2023 |
6-K |
On January 5, 2023, Biophytis S.A. issued a press release announcing its participation in two major investor conferences in January, in the United States and in France : the JP Morgan Healthcare Conference and the Invest Securities Biomed Event. |
|
| November 30, 2022 |
6-K |
On November 30, 2022, Biophytis S.A. issued a press release announcing the organization of a webcast with key opinion leaders (KOL) on the phase 2-3 COVA study results of Sarconeos (Ruvembri) in the treatment of pneumonia in COVID-19 patients at risk of respiratory failure. |
|
| October 31, 2022 |
6-K |
On October 31, 2022, Biophytis S.A. issued a press release announcing the publication of its key financial figures as at 30 June 2022 and a restatement of the financial statements published as of December 31st, 2021 and providing and update on the operational milestones. |
|
| October 26, 2022 |
6-K |
On October 26, 2022, Biophytis S.A. issued a press release announcing receipt of Nasdaq Notice. |
|
| September 15, 2022 |
6-K |
On September 15, 2022, Biophytis S.A. issued a press release announcing that the company will participate in HCW 24th Annual Global Investment conference. |
|
| September 13, 2022 |
6-K |
On September 13, 2022, Biophytis S.A. issued a press release announcing that the Paris Court of appeal rules in favour of Biophytis in the case against Negma Group Ltd. |
|
| September 07, 2022 |
6-K |
On September 7, 2022, Biophytis S.A. issued a press release announcing very promising top line results of its phase 2-3 COVA clinical study in COVID-19 related to respiratory failure. |
|
| July 04, 2022 |
6-K |
On July 4, 2022, Biophytis S.A. issued a press release providing an update on the development of Sarconeos (Ruvembri) in Covid-19 at the 4th Annual Longevity Therapeutics Summit. |
|
| June 30, 2022 |
6-K |
On June 30, 2022, Biophytis S.A. issued a press release announcing the drawing of the second tranche of ORNANE under the 2021 Atlas Contract for €4 million. |
|
| June 27, 2022 |
6-K |
On June 27, 2022, Biophytis S.A. issued a press release presenting the development of Sarconeos (Ruvembri) in Phase 3 for the treatment of Sarcopenia at the 15th SCWD International Congress. |
|
| June 22, 2022 |
6-K |
On June 22, 2022, Biophytis S.A. issued a press release announcing the results of the Combined General Meeting held on June 21, 2022. |
|
| June 16, 2022 |
6-K |
On June 16, 2022, Biophytis S.A. issued a press release presenting preclinical efficacy data for Sarconeos (Ruvembri) in Spinal Muscular Atrophy (SMA), a rare neuromuscular disease. |
|
| June 3, 2022 |
6-K |
On June 3, 2022, Biophytis S.A. issued a press release announcing the Convening of Another Combined General Meeting at a Later Date. |
|
| May 12, 2022 |
6-K |
On May 12, 2022, Biophytis S.A. issued a press release announcing its participation at the Bio International Convention in San Diego from the 13th to the 16th of June |
|
| April 21, 2022 |
20-F |
Annual Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934
For The Fiscal Year Ended December 31, 2021 |
|
| April 19, 2022 |
6-K |
On April 19, 2022, Biophytis S.A. issued a press release announcing that the company will present Sarconeos (Ruvembri) Development Program in Sarcopenia at the 12th annual International Conference on Frailty and Sarcopenia Research (ICFSR) in Boston, April 20-22, 2022 |
|
| April 7, 2022 |
6-K |
On April 7, 2022, Biophytis S.A. issued a press release announcing 2021 Operational and Financial Results and Gives Updates on 2022 Perspectives |
|
| April 5, 2022 |
6-K |
On April 5, 2022, Biophytis S.A. issued a press release announcing the appointment of Philippe Rousseau as Chief Financial Officer |
|
| March 16, 2022 |
6-K |
On March 16, 2022, Biophytis S.A. issued a press release announcing that the company will participate in a key conference on mobility for the elderly |
|
| February 4, 2022 |
6-K |
On February 3, 2022, Biophytis S.A. issued a press release announcing that the company received approval from ANVISA (Brazil) to give access to Sarconeos (Ruvembri) to hospitalized COVID-19 patients through an Expanded Access Program |
|
| December 23, 2021 |
6-K |
On December 22, 2021, Biophytis S.A. issued a press release announcing the drawing of the last tranche of ORNANE under the 2020 Atlas contract for 3 million. |
|
| December 17, 2021 |
6-K |
On December 16, 2021, Biophytis S.A. issued a press release announcing that the company is to meet with FDA to advance Sarconeos (Ruvembri) development in Sarcopenia from Phase 2 to Phase 3 |
|
| November 23, 2021 |
6-K |
On November 22, 2021, Biophytis S.A. issued a press release announcing the obtaining of a new 10M€ loan structure with Kreos Capital |
|
| November 15, 2021 |
6-K |
On November 15, 2021, Biophytis S.A. issued a press release announcing US centers to restart recruitment for the COVA phase 2-3 study with Sarconeos (Ruvembri) in COVID 19 |
|
| October 29, 2021 |
6-K |
On October 29, 2021, Biophytis S.A. issued a press release reporting Restated Financial Statements for Previous Periods and as of June 30, 2021. |
|
| October 29, 2021 |
20-F |
Annual Report Pursuant To Section 13 Or 15(D) Of The Securities Exchange Act Of 1934
For The Fiscal Year Ended December 31, 2020 |
|
| October 29, 2021 |
6-K |
On October 28, 2021, Biophytis S.A. (the “Company” issued its Interim Financial Report for the first half of fiscal year 2021. |
|
| October 06, 2021 |
6-K |
Biophytis S.A. issued a press release announcing it will host a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (Ruvembri) for the treatment of COVID-19 and Sarcopenia |
|
| October 05, 2021 |
6-K |
On October 4, 2021, Biophytis S.A. issued a press release announcing the drawing of 2 new tranches of ORNANE under the 2020 Atlas contract for € 6 million |
|
| October 04, 2021 |
6-K |
Biophytis announces promising full results from the SARA-INT Phase 2b trial of Sarconeos (Ruvembri) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR)
September 29 – October 2, 2021 |
|
| September 30, 2021 |
6-K |
Biophytis to Present Full Results from the SARA-INT Phase 2b Trial of Sarconeos (Ruvembri) in Sarcopenia at the 11th annual International Conference on Frailty and Sarcopenia Research (ICFSR) September 29–October 2, 2021 |
|
| September 17, 2021 |
6-K |
Biophytis reports H1 2021 financial results and provides business update |
|
| September 15, 2021 |
6-K |
Biophytis announces DMC second interim analysis efficacy results in the promising zone allowing continuation of phase 2/3 COVA study with Sarconeos (Ruvembri) in COVID-19 |
|
| June 30, 2021 |
6-K |
Biophytis announces that the results of SARA-INT Phase 2 Trial with Sarconeos (Ruvembri) in Sarcopenia will be released by August 2021 |
|
| June 30, 2021 |
6-K |
Biophytis announces that it will secure the manufacturing of Sarconeos (Ruvembri) for COVID-19 with a global CDMO and the next milestones for the COVA Phase 2-3 study |
|
| June 18, 2021 |
6-K |
Biophytis announces new convertible bonds financing upt to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million |
|
| May 12, 2021 |
6-K |
Biophytis Completed the Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (Ruvembri) in COVID-19 allowing the 2nd Interim Analysis |
|
| May 11, 2021 |
6-K |
Results of the Combined General Meeting on May 10, 2021 |
|
| April 30, 2021 |
6-K |
Biophytis Second Combined General Meeting to take place on May 10, 2021 without the physical presence of its shareholers |
|
| April 29, 2021 |
6-K |
Biophytis Receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD |
|
| April 27, 2021 |
6-K |
Convening of another Combined General Meeting at a later date |
|
| April 26, 2021 |
6-K |
Biophytis gives operational perspectives on its Sarconeos (Ruvembri) ahead of its upcoming AGM on April 26, 2021 |
|
| March 22, 2021 |
6-K |
Biophytis gives update on its Phase 2-3 COVA study on COVID-19 |
|
| March 19, 2021 |
6-K |
Judgment of the Paris Commercial Court of March 16, 2021 in the case of Biophytis against Negma Group Ltd |
|
| March 12, 2021 |
6-K |
Annual General Meeting will take place on April 26, 2021 |
|
| March 11, 2021 |
20-F |
Annual Report for the Fiscal Year Ended Dec 31, 2020 |
|
| Feb 26, 2021 |
6-K |
Biophytis Reports 2020 Full Year Results |
|
| Feb 17, 2021 |
6-K |
Expansion of Patient Recruitment for Part 2 of the Phase 2-3 COVA Trial |
|
| Feb 16, 2021 |
6-K |
Report of Foreign Private Issuer |
|
| Feb 9, 2021 |
|
Final Prospectus |
|
| Feb 9, 2021 |
F-1 |
Amendment No 3 |
|
| Feb 8, 2021 |
FWP |
Free Writing Prospectus |
|
| Feb 4, 2021 |
F-8A |
For Registration of Certain Classes of Securities Pursuant to Section 12(b) or (g) |
|
| Feb 4, 2021 |
F-1 |
Amendment No 2 |
|
| Feb 2, 2021 |
FWP |
Free Writing Prospectus |
|
| Feb 2, 2021 |
F-1 |
Amendment No 1 |
|
| Jan 19, 2021 |
F-1 |
Form F-1 |
|
| Dec 23, 2020 |
F-1 |
Draft Registration Statement |
|
| Nov 20, 2020 |
F-1 |
Draft Registration Statement |
|
